Michael Milken

Summary

Michael Milken reshaped American corporate finance from a single desk in Beverly Hills. As head of the high-yield bond department at Drexel Burnham Lambert, he turned the disreputable "junk" bond into a mainstream instrument, financing leveraged buyouts and capital-starved companies that the established banks would not touch. By the late 1980s he was the highest-paid financier in the country; Drexel paid him a reported $550 million in 1987 alone, and his influence over the credit markets was so concentrated that his annual Beverly Hills conference was nicknamed the "Predators' Ball."

That dominance collapsed under a federal securities investigation that began in 1986 and was advanced by the cooperation of arbitrageur Ivan Boesky. In March 1989 a grand jury returned a 98-count indictment charging racketeering, securities fraud and mail fraud. In April 1990 Milken pleaded guilty to six felony counts of securities and tax violations and agreed to pay $600 million in fines and penalties. He was sentenced to ten years in prison, served roughly 22 months after the sentence was reduced, and was barred for life from the securities industry.

Released in 1993 and diagnosed with advanced prostate cancer that same year, Milken rebuilt a very large fortune through private investing and ventures such as the education company Knowledge Universe, and he poured money and organizational energy into medical research. He founded the Prostate Cancer Foundation and built the Milken Institute into a prominent economic think tank, recasting himself as a philanthropist and convener.

In February 2020 President Donald Trump granted Milken a full pardon, citing his cancer-research philanthropy. His story remains contested: critics see a financier who broke the law and escaped lightly, while supporters point to a record of capital-market innovation and decades of disease-fighting giving. Notably, despite the popular "insider trading" label, the six counts he admitted concerned securities reporting, recordkeeping and tax matters, not insider trading.

The First Fortune

Michael Milken built his career on a contrarian thesis: that bonds rated below investment grade were systematically underpriced, and that their higher yields more than compensated for their higher default risk. After studying the historical performance of low-rated debt, he joined Drexel Firestone (later Drexel Burnham Lambert) and, through the 1970s, made the firm the dominant trader and underwriter of high-yield bonds. He moved his operation to Beverly Hills in 1978, where the high-yield department became the profit engine of the entire firm.

In the 1980s Milken's market matured from trading existing junk into underwriting brand-new high-yield issues, which gave smaller and growth-oriented companies access to capital they could not raise from banks or the blue-chip bond market. The same machinery financed a wave of leveraged buyouts and hostile takeovers, making Milken a feared and courted figure on Wall Street. His confidence that he could place almost any issue with his network of buyers — the "highly confident" letter — gave corporate raiders enormous reach.

The scale of his personal earnings was unprecedented. Drexel's compensation of Milken across the mid-1980s ran into the hundreds of millions of dollars annually, including the roughly $550 million paid in 1987 — a figure that exceeded the earnings of the firm itself in some measures and made him, by a wide margin, the best-paid person in American finance.

The Fall

The downfall began in 1986, when the government's insider-trading case against arbitrageur Ivan Boesky produced a cooperator who pointed investigators toward Drexel and Milken. Among the allegations was that Boesky had paid Drexel $5.3 million in 1986, characterized as a consulting fee, that actually represented Milken's share of profits from improper trading arrangements. The U.S. Attorney for the Southern District of New York, Rudolph Giuliani, pursued a sweeping criminal investigation, while the SEC pressed a parallel civil case.

In March 1989 a federal grand jury indicted Milken, his brother Lowell and a colleague on 98 counts, including racketeering, securities fraud and mail fraud. Drexel itself, facing potential prosecution, pleaded guilty to six felonies in 1989, paid $650 million, and severed ties with Milken; the firm filed for bankruptcy in early 1990. Stripped of the institution that had backed him, Milken negotiated a plea.

In April 1990 Milken pleaded guilty to six felony counts involving securities and tax violations — including conspiracy, securities and reporting violations, aiding and abetting an improper filing, and tax-related conduct — and agreed to pay $600 million in fines and disgorgement. Crucially, none of the six counts was insider trading, despite the label that has followed him in the press. Judge Kimba Wood sentenced him in November 1990 to ten years in prison. His cooperation in other matters later led to a reduction of the sentence, and he served roughly 22 months before his release in 1993. He was permanently barred from the securities industry, and additional civil settlements pushed his total payouts well beyond the criminal fine, with figures often cited near or above $1 billion.

The Comeback

Milken left prison in 1993 and was almost immediately diagnosed with advanced prostate cancer, told the disease was serious. Barred for life from the securities business, he could not return to his old trade, so he rebuilt his wealth as a private investor and entrepreneur. With partners including Larry Ellison, he co-founded education and human-capital ventures, most prominently Knowledge Universe, assembling a portfolio of education and training companies. By the 2010s his estimated net worth had returned to the billions, the great majority of it accumulated after his release.

The cancer diagnosis redirected much of his energy into medical philanthropy. He founded the Prostate Cancer Foundation, which became one of the largest private funders of prostate-cancer research, and he applied an investor's discipline to grant-making — funding aggressively, demanding results and accelerating collaboration among researchers. He also poured resources into broader cancer and public-health research and into the economic policy work of the Milken Institute, the think tank he established that hosts a closely watched annual conference in Los Angeles.

The reputational rehabilitation was deliberate and decades long. By recasting himself as a philanthropist and a convener of leaders in finance, medicine and policy, Milken built a second public identity distinct from the 1980s financier. The arc reached a formal endpoint in February 2020, when President Trump granted him a full pardon, explicitly crediting his cancer-research philanthropy — a clemency supported by a roster of prominent business figures and criticized by those who saw it as erasing accountability for financial crimes.

The Turnaround

Legacy

Milken's legacy in finance is genuinely double-edged. He is widely credited with democratizing access to capital — letting non-investment-grade companies, including many that became household names, raise money they could not otherwise have obtained — and with building the modern high-yield market that still funds a large share of corporate borrowing. He is just as widely cited as a symbol of 1980s excess and of the criminal enforcement that followed, his name shorthand for an era of takeovers and outsized pay.

In medicine and policy his second act is less contested. The Prostate Cancer Foundation he founded has funded research credited with advancing treatment and screening, and the Milken Institute has become a fixture of economic and public-health discussion. His method — applying venture-style urgency and accountability to philanthropy — has been studied and imitated by other large donors.

The 2020 pardon closed the legal chapter without settling the moral one. To admirers, Milken is a financial innovator who paid an enormous price, beat cancer and devoted his remaining decades to saving lives. To critics, he is a convicted felon whose wealth and connections bought a softer landing than most defendants receive. Both readings draw on the same verifiable record, which is precisely what makes his a defining second-act story of American finance.

References

• Michael Milken Wikipedia
• Trump pardons Michael Milken, face of 1980s insider trading scandals CNBC
• Who is Michael Milken, the 'junk bond king' Trump just pardoned? The Washington Post
• A Look At The Newly Pardoned Michael Milken, A 'Junk Bond King' Turned Philanthropist NPR
• Jury Indicts Milken in Drexel Fraud Case The Washington Post